Oral ibandronate reduces activation frequency to healthy premenopausal levels in women with postmenopausal osteoporosis

被引：0
|
作者：
不详
机构：
来源：
CALCIFIED TISSUE INTERNATIONAL | 2006年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S155 / S156
页数：2
相关论文
共 50 条
  • [41] Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
    Chesnut, CH
    Skag, A
    Christiansen, C
    Recker, R
    Stakkestad, JA
    Hoiseth, A
    Felsenberg, D
    Huss, H
    Gilbride, J
    Schimmer, RC
    Delmas, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) : 1241 - 1249
  • [42] Oral clodronate significantly reduces fracture risk in women with postmenopausal or secondary osteoporosis.
    McCloskey, EV
    Selby, P
    Davies, M
    Francis, R
    Robinson, J
    Kayan, K
    Beneton, M
    Jalava, T
    Pylkkanen, L
    Kenrali, J
    Kanis, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S227 - S227
  • [43] Similar safety profile of intravenous ibandronate injection and daily oral ibandronate in postmenopausal osteoporosis: The DIVA study.
    Sambrook, P
    Bianchi, G
    Olszynski, WP
    Leigh, C
    Masanauskaite, D
    Bonvoisin, B
    Emkey, R
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S296 - S296
  • [44] Oral daily ibandronate rapidly and significantly reduces the risk of new moderate and severe vertebral fractures after 1, 2 and 3 years in postmenopausal women with osteoporosis
    Felsenberg, D
    Papapoulos, SE
    Miller, P
    Hughes, C
    Schimmer, RC
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S70 - S70
  • [45] Monthly oral ibandronate significantly reduces bone resorption in postmenopausal osteoporosis: 1-year results from MOBILE.
    Recker, RR
    Kendler, DL
    Adami, S
    Hughes, C
    Dumont, E
    Schimmer, RC
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S94 - S94
  • [46] The MOTION study: Tolerability of monthly ibandronate and weekly alendronate in women with postmenopausal osteoporosis
    Delmas, P. D.
    Lewiecki, E. M.
    Ragi-Eis, S.
    Sedarati, F.
    Leigh, C.
    Cosman, F.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S327 - S327
  • [47] Clinical and nonvertebral fracture risk is reduced with the use of ibandronate in women with postmenopausal osteoporosis
    Miller, P. D.
    Harris, S. T.
    Blumentals, W. A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S451 - S451
  • [48] Cost-effectiveness of ibandronate injection IV in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates
    Lynch, N. O.
    Earnshaw, S. R.
    Graham, C. N.
    Middelhoven, H.
    OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S11 - S12
  • [49] Monthly oral ibandronate is effective and safe therapy for women with postmenopausal osteoporosis: Mobile 1-year results.
    Epstein, S
    Bolognese, MA
    Miller, P
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S196 - S196
  • [50] Ibandronate IV injection is cost-effective in the treatment of UK women with postmenopausal osteoporosis who are intolerant to oral bisphosphonates
    Lynch, N. O.
    Earnshaw, S.
    Graham, C.
    Patroe, V.
    Boisdron, J.
    Middelhoven, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 529 - 529
12345